Saijun Mo

Dr. Saijun Mo


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
SZSong Zhang
Song Zhang
WCWenbo Cao
Wenbo Cao
MYMingjin Yue
Mingjin Yue
NZNaigang Zheng
Naigang Zheng
THTao Hu
Tao Hu
SMSaijun Mo
Saijun Mo

31 May 2023 in Cellular Signalling
Verified
Journal Article
Closed access
XDXiaoxuan Duan
Xiaoxuan Duan
YCYihuan Chen
Yihuan Chen
KZKai Zhang
Kai Zhang
WCWei Chen
Wei Chen
JZJun Zhao
Jun Zhao
JLJing Lu
Jing Lu

21 March 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
QWQi-Ying Wei
Qi-Ying Wei
FJFeng Jin
Feng Jin
ZWZhong-Yu Wang
Zhong-Yu Wang
BLBing-Jie Li
Bing-Jie Li
WCWen-Bo Cao
Wen-Bo Cao
SMSaijun Mo
Saijun Mo
Esophageal squamous cell carcinoma (ESCC) is a malignant epithelial tumor, characterized by squamous cell differentiation, it is the sixth leading cause of cancer-related deaths globally. The increased mortality rate of ESCC patients is predominantly due to the advanced stage of the disease when discovered, coupled with higher risk of metastasis, which is an exceedingly malignant characteristic of cancer, frequently leading to a high mortality rate. Unfortunately, there is currently no specific and effective marker to predict and treat metastasis in ESCC. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules, approximately 22 nucleotides in length. miRNAs are vital in modulating gene expression and serve pivotal regulatory roles in the occurrence, progression, and prognosis of cancer. Here, we have examined the literature to highlight the intimate correlations between miRNAs and ESCC metastasis, and show that ESCC metastasis is predominantly regulated or regulated by genetic and epigenetic factors. This review proposes a potential role for miRNAs as diagnostic and therapeutic biomarkers for metastasis in ESCC metastasis, with the ultimate aim of reducing the mortality rate among patients with ESCC.

8 June 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LBLiuyang Bai
Liuyang Bai
LYLiangying Yan
Liangying Yan
YGYaping Guo
Yaping Guo
LHLuyun He
Luyun He
ZSZhiyan Sun
Zhiyan Sun
SMSaijun Mo
Saijun Mo
Background: Perineural invasion (PNI) is a malignant metastatic mode of tumors and has been reported in many tumors including esophageal cancer (EC). However, the role of PNI in EC has been reported differently. This systematic review and meta-analysis aims to focus on the role of PNI in EC.Methods: Eight databases of CNKI, VIP, Wanfang, Scopus, Wiley, ISI, PubMed, and EBSCO are used for literature search. The association of PNI with gender, pathological stages of T and N (pT and pN), lymphovascular invasion (LVI), lymph node metastasis, 5-year overall survival (OS), and 5-year disease-free survival (DFS) was examined in the meta-analysis by Revman5.0 Software. The pooled OR/HR and 95% CI were used to assess the risk and prognostic value.Results: Sixty-nine published studies were screened for analysis of PNI in EC. The incidence of PNI in esophageal squamous carcinoma (ESCC) and esophageal adenocarcinoma (EAC) was different, but not statistically significant (p &gt; 0.05). The PNI-positive patients had a significantly higher risk of pT stage (OR = 3.85, 95% CI = 2.45–6.05, p < 0.00001), pN stage (OR = 1.86, 95% CI = 1.52–2.28, p < 0.00001), LVI (OR = 2.44, 95% CI = 1.55–3.85, p = 0.0001), and lymph node metastasis (OR = 2.87, 95% CI = 1.56–5.29, p = 0.0007). Furthermore, the cumulative analysis revealed a significant correlation between PNI and poor OS (HR = 1.37, 95% CI = 1.24–1.51, p < 0.0001), as well as poor DFS (HR = 1.55, 95% CI = 1.38–1.74, p < 0.0001).Conclusion: PNI occurrence is significantly related to tumor stage, LVI, lymph node metastasis, OS, and DFS. These results indicate that PNI can serve as an indicator of high malignant degree and poor prognosis in EC.

1 January 2024 in AIMS Neuroscience
Verified
Journal Article
Open access
PDF file
YZYinghua Zhang
Yinghua Zhang
XWXinyue Wei
Xinyue Wei
WZWenhao Zhang
Wenhao Zhang
FJFeng Jin
Feng Jin
WCWenbo Cao
Wenbo Cao
SMSaijun Mo
Saijun Mo
Brain-derived neurotrophic factor (BDNF) is a predominant neurotrophic factor in the brain, indispensable for neuronal growth, synaptic development, neuronal repair, and hippocampal neuroplasticity. Among its genetic variants, the BDNF Val66Met polymorphism is widespread in the population and has been associated with the onset and aggravation of diverse pathologies, including metabolic conditions like obesity and diabetes, cardiovascular ailments, cancer, and an array of psychiatric disorders. Psychiatric disorders constitute a broad category of mental health issues that influence mood, cognition, and behavior. Despite advances in research and treatment, challenges persist that hinder our understanding and effective intervention of these multifaceted conditions. Achieving and maintaining stable body weight is pivotal for overall health and well-being, and the relationship between psychiatric conditions and body weight is notably intricate and reciprocal. Both weight gain and loss have been linked to varying mental health challenges, making the disentanglement of this relationship critical for crafting holistic treatment strategies. The BDNF Val66Met polymorphism's connection to weight fluctuation in psychiatric patients has garnered attention. This review investigated the effects and underlying mechanisms by which the BDNF Val66Met polymorphism moderates body weight among individuals with psychiatric disorders. It posits the polymorphism as a potential biomarker, offering prospects for improved monitoring and therapeutic approaches for mental illnesses.

10 January 2023 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZXZiteng Xie
Ziteng Xie
XXXiaomeng Xu
Xiaomeng Xu
WCWenbo Cao
Wenbo Cao
LHLuyun He
Luyun He
CKChen Kou
Chen Kou
SMSaijun Mo
Saijun Mo
MicroRNA (miRNA), a non‑coding single‑stranded RNA molecule with a length of 21‑25 nucleotides transcripts, has been identified to play important roles in tumorigenesis and shows great potential applications in cancer diagnosis, prognosis and therapy. Brain derived neurotrophic factor (BDNF) is a member of the nerve growth factor family and usually serves as a biomarker in neurological and neuropsychiatric diseases for diagnosis and treatment by regulating its high‑affinity receptor TrkB (Tyrosine Kinase Receptor B). Abnormal expression of BDNF is also closely related to the development of cancer, cancer‑related pain and depression. However, little significant progress has been made in the application of BDNF in cancers. Recent studies have shown that the expression of BDNF is directly regulated by a cluster of miRNAs. This review concluded and discussed the role and mechanism of miRNAs targeting BDNF in cancers, and provided novel insights into the diagnosis and therapy of cancer in the future.